+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 120Years
All Genders
ID07388563

Study of Azacitidine Combined with Abatacept for Relapsed or Refractory T-Cell Lymphoma Evaluating Dose and Tumor Response

Led by National Cancer Institute (NCI) · Updated on 2026-10-20

20

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of azacitidine and abatacept as a possible treatment for people with relapsed or refractory T-cell lymphoma, a blood cancer affecting immune system cells. This condition typically has poor outcomes, with survival less than one year if it does not respond to treatment or returns after treatment. The trial aims to find out if this drug combination can shrink tumors and to determine the best dose and response rate. Participants receive azacitidine by injection under the skin on the thigh, abdomen, or upper arm, and abatacept through an intravenous infusion into a vein in the arm. Treatment is given in 28-day cycles for up to 13 cycles. During the first cycle, participants visit the clinic on days 1 and 15, then come on the first 5 or 7 days of each subsequent cycle. After six cycles, those who respond may continue azacitidine alone for up to six more cycles. Participants will undergo physical exams, blood tests, heart function tests, and imaging scans to monitor tumors throughout the study. Tumor tissue samples may also be taken. Follow-up visits will continue for up to five years after treatment ends to assess response and safety. Researchers will measure tumor shrinkage, treatment tolerance, and overall response over this time.

CONDITIONS

Brief Title

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Research Team

N

National Cancer Institute Referral Offic

S

Samuel Y Ng, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here